By Adria Calatayud

 

Roche Holding's Alecensa drug reduced the risk of disease recurrence or death in a phase 3 trial for a type of non-small cell lung cancer at an early stage, the company said Wednesday.

The Swiss pharmaceutical giant said a primary analysis of the study results showed Alecensa reduced the risk of disease recurrence or death by 76% compared with platinum-based chemotherapy, demonstrating a statistically significant and clinically meaningful improvement in disease-free survival.

The safety and tolerability of the drug in the trial were consistent with previous studies and no unexpected safety findings were observed, Roche said.

The company said it is conducting further analysis of overall survival estimates given that data were immature at this stage.

Roche will submit data from the trial to global health authorities, including the U.S. Food and Drug Administration and the European Medicines Agency, it said.

 

Write to Adria Calatayud at adria.calatayud@dowjones.com

 

(END) Dow Jones Newswires

October 18, 2023 01:59 ET (05:59 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Roche (QX) 차트를 더 보려면 여기를 클릭.
Roche (QX) (USOTC:RHHBY)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Roche (QX) 차트를 더 보려면 여기를 클릭.